Brainstorm announces new survival data from expanded access program cohort: remarkably 90% of als patients survived over 5 years with nurown®

New york , june 16, 2025 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced new survival data from 10 participants in its expanded access program (eap) for nurown® (autologous msc-ntf cells) in amyotrophic lateral sclerosis (als). the eap enrolled 10 participants who had previously completed the phase 3 clinical trial.
BCLI Ratings Summary
BCLI Quant Ranking